171 related articles for article (PubMed ID: 25895986)
1. CCR5 Expression Levels in HIV-Uninfected Women Receiving Hormonal Contraception.
Sciaranghella G; Wang C; Hu H; Anastos K; Merhi Z; Nowicki M; Stanczyk FZ; Greenblatt RM; Cohen M; Golub ET; Watts DH; Alter G; Young MA; Tsibris AM
J Infect Dis; 2015 Nov; 212(9):1397-401. PubMed ID: 25895986
[TBL] [Abstract][Full Text] [Related]
2. Effects of three long-acting reversible contraceptive methods on HIV target cells in the human uterine cervix and peripheral blood.
Li L; Zhou J; Wang W; Huang L; Tu J; Baiamonte L; Stark M; Mills M; Hope TJ; Drobnis EZ; Quayle AJ; Schust DJ
Reprod Biol Endocrinol; 2019 Feb; 17(1):26. PubMed ID: 30795774
[TBL] [Abstract][Full Text] [Related]
3. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
4. Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression.
Morrison CS; Hofmeyr GJ; Thomas KK; Rees H; Philip N; Palanee-Phillips T; Nanda K; Nair G; Onono M; Mastro TD; Lind M; Heffron R; Edward V; Deese J; Beksinska M; Beesham I; Stringer JSA; Baeten JM; Ahmed K;
AIDS Res Hum Retroviruses; 2020 Aug; 36(8):632-640. PubMed ID: 32394723
[TBL] [Abstract][Full Text] [Related]
5. Increased Cervical CD4
Lajoie J; Tjernlund A; Omollo K; Edfeldt G; Röhl M; Boily-Larouche G; Cheruiyot J; Kimani M; Kimani J; Oyugi J; Broliden K; Fowke KR
AIDS Res Hum Retroviruses; 2019 Mar; 35(3):236-246. PubMed ID: 30585733
[TBL] [Abstract][Full Text] [Related]
6. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
[TBL] [Abstract][Full Text] [Related]
7. Effects of human immunodeficiency virus type 1 infection on CCR5 and CXCR4 coreceptor expression on CD4 T lymphocyte subsets in infants and adolescents.
Tuttle DL; Coberley CR; Xie X; Kou ZC; Sleasman JW; Goodenow MM
AIDS Res Hum Retroviruses; 2004 Mar; 20(3):305-13. PubMed ID: 15117454
[TBL] [Abstract][Full Text] [Related]
8. Changes in genital tract immune cell populations after initiation of intrauterine contraception.
Achilles SL; Creinin MD; Stoner KA; Chen BA; Meyn L; Hillier SL
Am J Obstet Gynecol; 2014 Nov; 211(5):489.e1-9. PubMed ID: 24834865
[TBL] [Abstract][Full Text] [Related]
9. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
Modesto W; de Nazaré Silva dos Santos P; Correia VM; Borges L; Bahamondes L
Eur J Contracept Reprod Health Care; 2015 Feb; 20(1):57-63. PubMed ID: 25160484
[TBL] [Abstract][Full Text] [Related]
10. Exploring the immunomodulatory role of depot medroxyprogesterones acetate and endogenous progesterone levels in HIV infected and uninfected women.
Mnqonywa N; Abbai N; Ragupathy V; Ramjee G; Hewlett I; Moodley D
BMC Res Notes; 2019 Nov; 12(1):745. PubMed ID: 31730016
[TBL] [Abstract][Full Text] [Related]
11. Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial.
Chinula L; Nelson JAE; Wiener J; Tang JH; Hurst S; Tegha G; Msika A; Ellington S; Hosseinipour MC; Mataya R; Haddad LB; Kourtis AP
Contraception; 2018 Sep; 98(3):193-198. PubMed ID: 29746813
[TBL] [Abstract][Full Text] [Related]
12. [Human immunodeficiency virus (HIV) co-receptors expression in mononuclear leucocytes (ML) of HIV+ patients].
Belmonte L; de Elizalde de Bracco MM; Ruibal-Ares B
Medicina (B Aires); 2001; 61(5 Pt 2):670-2. PubMed ID: 12058586
[TBL] [Abstract][Full Text] [Related]
13. Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial.
Bunjun R; Ramla TF; Jaumdally SZ; Noël-Romas L; Ayele H; Brown BP; Gamieldien H; Harryparsad R; Dabee S; Nair G; Onono M; Palanee-Phillips T; Scoville CW; Heller KB; Baeten JM; Bosinger SE; Burgener A; Passmore JS; Jaspan H; Heffron R
Clin Infect Dis; 2022 Nov; 75(11):2000-2011. PubMed ID: 35941737
[TBL] [Abstract][Full Text] [Related]
14. Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant.
Deese J; Philip N; Lind M; Ahmed K; Batting J; Beksinska M; Edward VA; Louw CE; Onono M; Palanee-Phillips T; Smit JA; Baeten JM; Donnell D; Mastro TD; Mugo NR; Nanda K; Rees H; Morrison C
Sex Transm Infect; 2021 Jun; 97(4):249-255. PubMed ID: 33208512
[TBL] [Abstract][Full Text] [Related]
15. Breast milk CD4+ T cells express high levels of C chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy.
Kourtis AP; Ibegbu CC; Theiler R; Xu YX; Bansil P; Jamieson DJ; Lindsay M; Butera S; Duerr A
J Infect Dis; 2007 Apr; 195(7):965-72. PubMed ID: 17330786
[TBL] [Abstract][Full Text] [Related]
16. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial.
Beksinska M; Issema R; Beesham I; Lalbahadur T; Thomas K; Morrison C; Hofmeyr GJ; Steyn PS; Mugo N; Palanee-Phillips T; Ahmed K; Nair G; Baeten JM; Smit J
EClinicalMedicine; 2021 Apr; 34():100800. PubMed ID: 33898953
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial.
Mugo NR; Stalter RM; Heffron R; Rees H; Scoville CW; Morrison C; Kourtis AP; Bukusi E; Beksinka M; Philip NM; Beesham I; Deese J; Edward V; Donnell D; Baeten JM;
Clin Infect Dis; 2022 Sep; 75(4):586-595. PubMed ID: 34910143
[TBL] [Abstract][Full Text] [Related]
18. Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome.
Brooks JP; Edwards DJ; Blithe DL; Fettweis JM; Serrano MG; Sheth NU; Strauss JF; Buck GA; Jefferson KK
Contraception; 2017 Apr; 95(4):405-413. PubMed ID: 27913230
[TBL] [Abstract][Full Text] [Related]
19. Effects of Depot Medroxyprogesterone Acetate Intramuscular Injection, Copper Intrauterine Device and Levonorgestrel Implant Contraception on Estradiol Levels: An Ancillary Study of the ECHO Randomized Trial.
Ryan R; Mussa A; Singtaa-Madliki M; Batting J; Balakrishna Y; Morroni C; Hofmeyr GJ
Front Glob Womens Health; 2022; 3():887541. PubMed ID: 35669313
[TBL] [Abstract][Full Text] [Related]
20. Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels.
Maritz MF; Ray RM; Bick AJ; Tomasicchio M; Woodland JG; Govender Y; Avenant C; Hapgood JP
PLoS One; 2018; 13(4):e0196043. PubMed ID: 29698514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
